Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid

Arthritis Research and Therapy

Volumn 12, Issue 5, 2010, Pages

  Li, Edmund K ^a   Zhu, Tracy Y ^a   Hung, Vivian Y ^a   Kwok, Anthony W ^a   Lee, Vivian W ^b   Lee, Kenneth K ^b   Griffith, James F ^a   Li, Martin ^a   Wong, Kong Chiu ^a   Leung, Ping Chung ^a   Qin, Ling ^a   Tam, Lai Shan ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; CALCIUM; IBANDRONIC ACID; PREDNISOLONE; 1-HYDROXYCHOLECALCIFEROL; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; GLUCOCORTICOID; HYDROXYCOLECALCIFEROL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BONE DENSITY; CHINESE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIP; HUMAN; LUMBAR SPINE; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FRACTURE; GENERAL APPARATUS, EQUIPMENT AND SUPPLIES; MIDDLE AGED; OSTEOPOROSIS; PHOTON ABSORPTIOMETRY;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; HYDROXYCHOLECALCIFEROLS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; OSTEOPOROSIS; PREDNISOLONE; TOMOGRAPHY SCANNERS, X-RAY COMPUTED;

EID: 77958042447     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3170     Document Type: Article

References (51)

1. Gordon C. Long-term complications of systemic lupus erythematosus. Rheumatology (Oxford) 2002, 41:1095-1100. 10.1093/rheumatology/41.10.1095, 12364626.
2. Kipen Y, Buchbinder R, Forbes A, Strauss B, Littlejohn G, Morand E. Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids. J Rheumatol 1997, 24:1922-1929.
3. Ramsey-Goldman R, Dunn JE, Huang CF, Dunlop D, Rairie JE, Fitzgerald S, Manzi S. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999, 42:882-890. 10.1002/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C, 10323443.
4. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000, 43:1801-1808. 10.1002/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O, 10943870.
5. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000, 15:1384-1392. 10.1359/jbmr.2000.15.7.1384, 10893688.
6. Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O, . European Vertebral Osteoporosis Study Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 2003, 14:61-68. 10.1007/s00198-002-1316-9, 12577186, European Vertebral Osteoporosis Study.
7. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13:777-787. 10.1007/s001980200108, 12378366.
8. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006, 79:129-137. 10.1007/s00223-006-0019-1, 16969593.
9. Borba VZ, Matos PG, da Silva Viana PR, Fernandes A, Sato EI, Lazaretti-Castro M. High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients. Lupus 2005, 14:529-533. 10.1191/0961203305lu2154oa, 16130509.
10. Bultink IE, Lems WF, Kostense PJ, Dijkmans BA, Voskuyl AE. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52:2044-2050. 10.1002/art.21110, 15986345.
11. Li EK, Tam LS, Griffith JF, Zhu TY, Li TK, Li M, Wong KC, Chan M, Lam CW, Chu FS, Wong KK, Leung PC, Kwok A. High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol 2009, 36:1646-1652. 10.3899/jrheum.081337, 19605677.
12. Li EK, Zhu TY, Tam LS, Hung VW, Griffith JF, Li TK, Li M, Wong KC, Leung PC, Kwok AW, Qin L. Bone microarchitecture assessment by high-resolution peripheral quantitative computed tomography in patients with systemic lupus erythematosus on corticosteroids. J Rheumatol 2010, 37:1473-1479. 10.3899/jrheum.091231, 20472932.
13. Boutroy S, Bouxsein ML, Munoz F, Delmas PD. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 2005, 90:6508-6515. 10.1210/jc.2005-1258, 16189253.
14. Sornay-Rendu E, Boutroy S, Munoz F, Delmas PD. Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. J Bone Miner Res 2007, 22:425-433. 10.1359/jbmr.061206, 17181395.
15. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis: Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 1998, 339:292-299. 10.1056/NEJM199807303390502, 9682041.
16. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997, 337:382-387. 10.1056/NEJM199708073370603, 9241127.
17. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial: European Corticosteroid-induced Osteoporosis Treatment Study. J Bone Miner Res 2000, 15:1006-1013. 10.1359/jbmr.2000.15.6.1006, 10841169.
18. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001, 44:1496-1503. 10.1002/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5, 11465699, American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
19. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999, 42:2309-2318. 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K, 10555025.
20. Adachi JD. Corticosteroid-induced osteoporosis. Int J Fertil Womens Med 2001, 46:190-205.
21. Gonnelli S, Rottoli P, Cepollaro C, Pondrelli C, Cappiello V, Vagliasindi M, Gennari C. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997, 61:382-385. 10.1007/s002239900352, 9351879.
22. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001, 44:202-211. 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W, 11212161.
23. Cooper C, Emkey RD, McDonald RH, Hawker G, Bianchi G, Wilson K, Schimmer RC. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:4609-4615. 10.1210/jc.2003-022029, 14557430.
24. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporosis Int 2003, 14:801-807. 10.1007/s00198-003-1425-0, 14610641.
25. Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation 2003, 76:1498-1502. 10.1097/01.TP.0000092523.30277.13, 14657693.
26. Cohen A, Sambrook P, Shane E. Management of bone loss after organ transplantation. J Bone Miner Res 2004, 19:1919-1932. 10.1359/jbmr.040912, 15537434.
27. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN, HORIZON I. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009, 373:1253-1263. 10.1016/S0140-6736(09)60250-6, 19362675.
28. McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH, Ensrud KE, Burdeska A, Mills T, . Oral Ibandronate Study Group Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res 2004, 19:11-18. 10.1359/jbmr.0301202, 14753731, Oral Ibandronate Study Group.
29. McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. Bone 2009, 44:418-422. 10.1016/j.bone.2008.09.011, 18950736.
30. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005, 20:1315-1322. 10.1359/JBMR.050313, 16007327.
31. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006, 65:654-661. 10.1136/ard.2005.044958, 1798147, 16339289.
32. Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, Wasnich RD, Watts NB, Schimmer RC, Recker RR. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005, 21:391-401. 10.1185/030079905X30752, 15811208.
33. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003, 9:2643-2658. 10.2174/1381612033453640, 14529538.
34. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992, 35:498-502. 10.1002/art.1780350502, 1575785.
35. Lynn HS, Lau EM, Au B, Leung PC. Bone mineral density reference norms for Hong Kong Chinese. Osteoporos Int 2005, 16:1663-1668. 10.1007/s00198-005-1899-z, 16027958.
36. Hildebrand T, Laib A, Müller R, Dequeker J, Rüegsegger P. Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 1999, 14:1167-1174. 10.1359/jbmr.1999.14.7.1167, 10404017.
37. Ringe JD, Cöster A, Meng T, Schacht E, Umbach R. Treatment of glucocorticoid-induced osteoporosis with Alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 1999, 65:337-340. 10.1007/s002239900708, 10485988.
38. Reginster JY, de Froidmont C, Lecart MP, Sarlet N, Defraigne JO. Alphacalcidol in prevention of glucocorticoid-induced osteoporosis. Calcif Tissue Int 1999, 65:328-331. 10.1007/s002239900706, 10485986.
39. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J Clin Invest 1998, 102:274-282. 10.1172/JCI2799, 508885, 9664068.
40. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Mienr Res 2001, 16:97-103.
41. Akahoshi S, Sakai A, Arita S, Ikeda S, Morishita Y, Tsutsumi H, Ito M, Shiraishi A, Nakamura T. Modulation of bone turnover by Alfacalcidol and/or alendronate does not prevent glucocorticoid-induced osteoporosis in growing minipigs. J Bone Miner Metab 2005, 23:341-350. 10.1007/s00774-005-0611-x, 16133683.
42. Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S, Kinney JH, Bonewald LF. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 2006, 21:466-476. 10.1359/JBMR.051103, 1797152, 16491295.
43. Bhattoa HP, Bettembuk P, Balogh A, Szegedi G, Kiss E. Bone mineral density in women with systemic lupus erythematosus. Clin Rheumatol 2002, 21:135-141. 10.1007/s10067-002-8272-9, 12086164.
44. Chavassieux PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates AJ, Hamdy NA, Malice MP, Freedholm D, Meunier PJ. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000, 15:754-762. 10.1359/jbmr.2000.15.4.754, 10780867.
45. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 2004, 34:736-746. 10.1016/j.bone.2003.12.013, 15050906.
46. Nuzzo S, Lafage-Proust MH, Martin-Badosa E, Boivin G, Thomas T, Alexandre C, Peyrin F. Synchrotron radiation microtomography allows the analysis of three-dimensional microarchitecture and degree of mineralization of human iliac crest biopsy specimens: effects of etidronate treatment. J Bone Miner Res 2002, 17:1372-1382. 10.1359/jbmr.2002.17.8.1372, 12162491.
47. Recker RR, Ste-Marie LG, Langdahl B, Masanauskaite D, Ethgen D, Delmas PD. Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral ibandronate osteoporosis vertebral fracture trial in North America and Europe study. J Clin Densitom 2009, 12:71-76. 10.1016/j.jocd.2008.10.006, 19084450.
48. Greenspan SL, Perera S, Recker R, Wagner JM, Greeley P, Gomberg BR, Seaman P, Kleerekoper M. Changes in trabecular microarchitecture in postmenopausal women on bisphonate therapy. Bone 2010, 46:1006-1010. 10.1016/j.bone.2009.12.025, 20051275.
49. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008, 23:6-16. 10.1359/jbmr.070906, 17892374.
50. Cohen A, Dempster DW, Müller R, Guo XE, Nickolas TL, Liu XS, Zhang XH, Wirth AJ, van Lenthe GH, Kohler T, McMahon DJ, Zhou H, Rubin MR, Bilezikian JP, Lappe JM, Recker RR, Shane E. Assessment of trabecular and cortical architecture and mechanical competence of bone by high-resolution peripheral computed tomography: comparison with transiliac bone biopsy. Osteoporos Int 2010, 21:263-273. 10.1007/s00198-009-0945-7, 19455271.
51. Sekhon K, Kazakia GJ, Burghardt AJ, Hermannsson B, Majumdar S. Accuracy of volumetric bone mineral density measurement in high-resolution peripheral quantitative computed tomography. Bone 2009, 45:473-479. 10.1016/j.bone.2009.05.023, 19501201.